NCT04188548 2025-06-04
EMBER
Eli Lilly and Company
Phase 1 Active not recruiting
Clinical Trials
4 trialsNCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT01623349 2021-02-10
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01708161 2018-09-13
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
Novartis
Phase 1/2 Terminated